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A152 Abstracts
The cost savings following the use of Iodixanol compared to Iopromide in coronar-
ography averaged 2287 RUB (72 USD) in common population, 2866 RUB (USD91) 
in patients with CKD, and 3427 RUB (US$109) in patients with diabetes mellitus and
CKD. CONCLUSIONS: The results of this study demonstrated Iodixanol to be cost-
saving compared to low-osmolar contrast media both in risk groups and in general
population.
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OBJECTIVES: The Take Control of Your Blood Pressure trial randomized 636 com-
munity-dwelling individuals with hypertension to evaluate the impact of a telephonic 
behavioral self-management intervention, home blood pressure monitoring, and both 
interventions combined compared to usual care on reducing systolic blood pressure 
(SBP) over 24 months. At 24 months, the combined intervention demonstrated a sig-
niﬁ cant 3.9 mmHg (95%CI: 0.9,6.9) reduction in SBP relative to usual care. Patients
randomized to home BP monitoring or the behavioral intervention had less improve-
ment (0.6 mmHg and 0.6 mmHg, respectively). A prospective economic evaluation 
was performed. METHODS: Measures of medical resource use costs were derived 
from electronic data representing medical care delivered within the Duke University 
Health System. Intervention-related costs, including patient time, were estimated using 
patient-level data collected during the trial, administrative records, and published unit
costs. Sensitivity analyses were conducted to evaluate the impact of changing assump-
tions about overhead costs and time between completed phone encounters when esti-
mating costs associated with the behavioral intervention. RESULTS: On average, over 
24 months, patients incurred $6,965 (SD  22,054) in inpatient costs and $8,676 (SD 
 9,368) in outpatient costs, with no signiﬁ cant differences across intervention groups. 
When applying base-case assumptions, 24-month intervention costs were estimated to
be $90 (SD  2) for home blood pressure monitoring, $345 (SD  64) for the behav-
ioral intervention ($31 per phone encounter) and $416 (SD  93) for the combined
intervention. In sensitivity analyses, the cost for each phone encounter ranged from
approximately $10 to $45. Patient time costs were estimated at $585 (SD  487) for
home monitoring, $55 (SD  16) for the behavioral intervention and $741 (SD  529) 
for the combined intervention. CONCLUSIONS: Home blood pressure monitoring 
and/or the behavioral intervention had little impact on medical resource use or costs
over 2 years. Our analysis demonstrated that these interventions are cost-additive to 
the health care system and that patients’ time costs are considerable.
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OBJECTIVES: To assessed the economic attractiveness of the Endeavor drug-eluting 
stent (DES) vs. the Driver bare metal stent (BMS) using 4-year follow-up information 
from the ENDEAVOR II clinical trial. METHODS: We used clinical, index procedure
and follow-up events data from subjects randomized to receive Endeavor (n  598)
vs. Driver (n  599), and applied Medicare cost and quality of life adjustments from
secondary sources. We compared differences in clinical endpoints, medical costs, and
quality adjusted survival through 4 years follow-up (1440 days). RESULTS: Patients
in both treatment groups had similar baseline characteristics. The use of Endeavor vs.
Driver reduced 4-year target vessel revascularization (TVR) rates per 100 subjects
(10.4 vs. 21.5; difference, 11.1; 95% conﬁ dence interval [CI], 16.0 to 6.1; p 
.001), with no difference in the rates per 100 subjects of death (5.0 vs. 5.2; difference, 
.2; 95% CI, 2.4 to 2.7; p  .90) or non-fatal myocardial infarction (MI) (3.2 vs. 
4.4; difference, 1.2; 95% CI, 3.4 to 1.0; p  .29). After discounting at a 3% annual 
rate, there were no differences in quality-adjusted survival days (1093 vs. 1090; dif-
ference, 3; 95% CI, 13 to 19; p  .69) and total medical costs ($21,483 vs. $21,680; 
difference, $198; 95% CI, $1608 to $1207, p  .78). CONCLUSIONS: The use of 
Endeavor vs. Driver was associated with a signiﬁ cant reduction in TVR through four
years follow-up with no difference in death, non-fatal MI, quality-adjusted survival,
or total medical costs. These results are comparable to those for other studies compar-
ing DES vs. BMS.
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OBJECTIVES: To evaluate the economic attractiveness of Endeavor vs. Cypher drug-
eluting stents (DES) in the ENDEAVOR III clinical trial. METHODS: We analyzed 
case report form information from subjects randomized to receive Endeavor (n  323)
vs. Cypher (n  113) stents, using quality of life adjustment and Medicare cost weights 
applied from secondary sources, and a $2100 cost for stents. We compared differences 
in outcomes and costs; and evaluated cost-effectiveness through 3-years follow-up
(1080 days). RESULTS: The use of Endeavor vs. Cypher stents reduced the 3-year
rates per 100 subjects of death or myocardial infarction (MI) (3.9 vs. 10.8; difference,
6.9; 95% conﬁ dence interval [CI], 0.8 to 9.9; p  .028), with no difference in 
target vessel revascularization rates (17.9 vs. 12.2; difference, 5.7; 95% CI, 3.9 to 
15.1; p  .23), but greater use of coronary artery bypass graft surgery (3.5 vs. 0.0;
difference 3.5; 95% CI, 1.3 to 5.7; p  .002). After discounting at 3% per annum, 
total medical costs for Endeavor vs. Cypher were similar ($23,353 vs. $21,657; dif-
ference, $1696; 95% CI, $1089 to $4482, p  .23), and the 3-year cost-effectiveness 
ratio was $57,002 per quality-adjusted life year. CONCLUSIONS: Use of Endeavor 
vs. Cypher led to reductions in death or MI, with no differences in other outcomes.
These ﬁ ndings are unexpected in DES comparisons. If future trials observe similar 
differences, the use of Endeavor vs. Cypher will be economically attractive by conven-
tional standards.
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OBJECTIVES: This study estimated medical expenditures attributable to coronary 
artery disease (CAD) in the US and investigated CAD case deﬁ nition in a nationally
representative sample. METHODS: Data from 2005 from the nationally representa-
tive Medical Expenditure Panel Survey (MEPS) were used to estimate the population 
with CAD and their medical expenditures. CAD cases were identiﬁ ed by patient-
reported myocardial infarction (MI), angina pectoris and/or coronary heart disease 
(CHD). Case deﬁ nition analysis used multivariable logistic regression. Person-level and
national expenditures were estimated on a logarithmic scale using a maximum 
likelihood Heckman selection model and Smearing re-transformation. All analyses 
employed Taylor series linearization methods to account for the complex survey design 
and adjusted for age, race, ethnicity, gender, income, education, and overweight status. 
RESULTS: In the 2005 civilian noninstitutionalized adult population (n  22262), 
there were 1016 CAD cases using a strict deﬁ nition of either MI or angina and 1266 
cases using a broad deﬁ nition including patient-reported CHD. Of those reporting
CHD (n  702), only 65% (n  458) had MI or angina . Females and blacks reporting
CHD were less likely to have MI or angina (OR  0.52, 0.39, p  0.01). Annual direct 
medical expenditures attributable to strictly deﬁ ned CAD were estimated to be $6456
($2007), on average, per person. Expenditures for broadly deﬁ ned CAD were $6453 
($2007). Based on this estimate and the weighted estimate of persons with CAD 
(approximately 9.8 million), the projected annual US medical expenditures attribut-
able to CAD are $63 billion ($2007). CONCLUSIONS: While CAD and CHD are
generally diagnosed by either MI or angina, patient-reported CHD is not consistent 
with this deﬁ nition. Consistency appears to vary with gender and race. While the CAD 
case deﬁ nition varies, expenditures do not. Results of this study indicate that direct 
medical expenditures associated with CAD in the US are substantial.
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OBJECTIVES: To identify drivers of post-hospital costs among ACS patients, includ-
ing treatment type received. Patients who are hospitalized with ACS have different 
treatment options, including revascularization procedures. While these procedures 
are expensive, there might be offsets in future health care costs by preventing 
adverse coronary events. METHODS: We studied commercially insured individuals, 
aged 18–64, with 36 months continuous enrollment in a large, geographically diverse 
health plan between January 2003 and December 2006. Patients were identiﬁ ed if 
they were hospitalized between January 1, 2004 and December 31, 2005 with a
diagnosis of ACS. A 1 year follow-up period was used and costs incurred after 
patients’ initial hospital discharge were examined. In addition to ordinary least squares
(OLS),, quantile-regression models (QRM) were used to identify drivers of post-
hospital costs. QRM make no assumption about the distribution of the error term
and provide quantile-speciﬁ c covariate effects, which is useful in applications with 
highly skewed data. RESULTS: OLS results indicated co-morbidity scores, prior 
health care costs and initial hospital diagnosis were main drivers of post-hospital 
discharge costs (p  0.01). Also, revascularization procedures during the initial 
hospitalization were not signiﬁ cantly associated with post-hospital costs. QRM con-
ﬁ rmed the other ﬁ ndings but showed, at the lower end of the post-hospital costs dis-
tribution, having revascularization procedures during the initial hospitalization was
signiﬁ cantly associated with higher post-hospital costs. This effect was not signiﬁ cant 
in the upper quantiles. CONCLUSIONS: In this study, initial hospital diagnosis, higher
co-morbidity scores and prior health care costs were associated with higher post-
hospital costs. Also, QRM showed revascularization procedures were drivers of cost 
for patients with lower post-hospital expenditures. This is an intuitive ﬁ nding con-
sidering patients who have revascularization procedures may have more follow-up 
care compared to those without revascularization. However, these patients may have
fewer secondary events requiring hospitalization, thus keeping them in the lower cost
quantiles.
